title: Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
abstract: OBJECTIVE
  To evaluate quality of life and patient preference for schizophrenia treatment in a community based study comparing the use of aripiprazole to the standard of care (SOC).
  
  
  METHODS
  This open-label, 26-week, multi-centre, randomised study compared aripiprazole with SOC (olanzapine, quetiapine or risperidone) in patients with schizophrenia (DSM-IV-TR criteria). The primary effectiveness variable was the mean total score of the Investigator Assessment Questionnaire (IAQ) at Week 26. The outcome research variables included the Preference of Medicine (POM) questionnaire, the Quality of Life Scale (QLS), and the EuroQoL-5D (EQ-5D). The results from these outcome research variables are the focus of this paper addressing quality of life and patient preference.
  
  
  RESULTS
  A total of 555 patients were randomised to receive aripiprazole (n=284) or SOC (n=271). The OC data at Week 26, reported that more respondents rated the study medication as 'much better' compared with their previous medication in the aripiprazole group versus SOC for patients (59% vs 35%, P<0.001) and caregivers (58% vs 30%, P=0.014). The improvement in QLS total score was also significantly greater in the aripiprazole group compared with SOC--mean change from baseline in QLS total score of 16.21 vs 10.01 (P<0.001) at Week 26 (OC data set). A greater proportion of patients (93% vs 85%; P=0.005) in the aripiprazole group had a satisfactory response on the EQ-5D Self Care Scale; all other EQ-5D scores were similar.
  
  
  CONCLUSIONS
  The study findings suggest that quality of life and patient medication preference measures were better for aripiprazole than for SOC.
authors.affiliation: South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK. david.taylor@slam.nhs.uk
authors.forename: David
authors.initials: D
authors.lastname: Taylor
authors.forename: Linda
authors.initials: L
authors.lastname: Hanssens
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Loze
authors.forename: Miranda
authors.initials: M
authors.lastname: Pans
authors.forename: Gilbert
authors.initials: G
authors.lastname: L'Italien
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Marcus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole; D002755:Choice Behavior; D003156:Community Mental Health Services / Q000458:organization & administration*; D003258:Consumer Behavior; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004358:Drug Therapy / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology*; D015363:Quinolones / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000628:therapy*; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole